Karyopharm Therapeutics Inc...has received a principal approval letter from the Israeli Ministry of Health, Israel's regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO...for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

XPOVIO is a nuclear export inhibitor indicated:...For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy...

Diffuse Large B-cell Lymphoma: Third-line and Subsequent Therapy…Selinexor (only after at least two lines of systemic therapy) Histologic Transformation of Indolent Lymphomas to DLBCL….Other recommended regimens...Selinexor (transformed FL; only after at least two lines of systemic therapy; including patients with disease progression after transplant or CAR T-cell therapy)

Karyopharm Therapeutics Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma (DLBCL)...Selinexor is currently being studied in the ongoing Phase 2b SADAL study in patients with relapsed or refractory DLBCL who are not eligible for stem cell transplantation...